Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: a Single-Center, Open-Label Split-Face Clinical Study

Total Page:16

File Type:pdf, Size:1020Kb

Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: a Single-Center, Open-Label Split-Face Clinical Study Efficacy and Safety of C/P Cream for Facial SD pISSN 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 28, No. 6, 2016 https://doi.org/10.5021/ad.2016.28.6.733 ORIGINAL ARTICLE Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study Hae Jeong Youn1, Soo Young Kim1, Minji Park2, Won Hee Jung2, Yang Won Lee1,3, Yong Beom Choe1,3, Kyu Joong Ahn1,3 1Department of Dermatology, Konkuk University School of Medicine, Seoul, 2Department of Systems Biotechnology, Chung-Ang University, Anseong, 3Research Institute of Medical Science, Konkuk University, Seoul, Korea Background: Seborrheic dermatitis (SD) is a multifactorial lient cream-treated left side. For the C/P cream, the MICs disease; Malassezia species play an important role in its were 0.625, 5, 0.625, and 2.5 mg/ml for Malassezia restricta, pathogenesis. Objective: We aimed to determine whether a M. globosa, M. sympodialis, and M. slooffiae, respectively. cream containing climbazole/piroctone olamine (C/P Conclusion: Based on the reduced casual sebum level and cream), antifungal agents with expected efficacy against extent of erythema, the antifungal activity of C/P cream Malassezia species, could improve SD symptoms. Methods: against Malassezia species seems useful for the treatment of We instructed 24 patients with mild-to-moderate SD to apply mild to moderate SD. (Ann Dermatol 28(6) 733∼739, 2016) the C/P cream and emollient cream on the right and left sides of the face, respectively, every morning and evening for 4 -Keywords- weeks. The casual sebum level (measured with SebumeterⓇ; Climbazole, Malassezia species, Piroctone olamine, Courage & Khazaka Electronic GmbH, Germany) and the ex- Seborrheic dermatitis tent of erythema (measured with MexameterⓇ; Courage & Khazaka Electronic GmbH) on the face were measured at baseline and after 4 weeks. The minimal inhibitory concen- INTRODUCTION tration (MIC) was determined to demonstrate the antifungal activity of the C/P cream. Results: The casual sebum level and Seborrheic dermatitis (SD) is a chronic dermatitis that af- erythema were measured at week 4, and the median values fects 1%∼3% of the population1. SD is characterised by demonstrated a quantitative improvement on the C/P sharply defined erythematous patches and plaques with cream-treated right side of the face compared to the emol- greasy-looking, yellowish scales on seborrheic areas such as the scalp, face, upper trunk, and flexures. The growth of Received November 13, 2015, Revised April 8, 2016, Accepted for Malassezia species was suggested as an important patho- publication April 11, 2016 genic factor of SD2,3, as demonstrated by studies that Corresponding author: Yang Won Lee, Department of Dermatology, Konkuk showed that SD was improved by the use of antifungal University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul agents4,5. Current treatment options include antifungal 05030, Korea. Tel: 82-2-2030-5172, Fax: 82-2-2030-5179, E-mail: 20050078@ kuh.ac.kr drugs, anti-inflammatory agents (steroids, calcineurin in- This is an Open Access article distributed under the terms of the Creative hibitors, and lithium salts), keratolytic agents, and photo- Commons Attribution Non-Commercial License (http://creativecommons. therapy. SD is usually treated with topical corticosteroids org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, and antifungals. However, prolonged use of topical ste- distribution, and reproduction in any medium, provided the original work is properly cited. roids may cause adverse effects such as skin atrophy, te- Copyright © The Korean Dermatological Association and The Korean langiectasia, rosacea, and acne. The use of topical anti- Society for Investigative Dermatology fungal agents in the treatment of mild SD is well Vol. 28, No. 6, 2016 733 HJ Youn, et al established. Itraconazole can be prescribed for moderate to DS+Ⓡ), which contains climbazole and piroctone ol- severe facial SD and result in significant clinical improve- amine, on the right side of the face and emollient cream ment and decrease in the growth of Malassezia species6. (AtodermⓇ; Bioderma Laboratoire Dermatologique), a The cream containing climbazole/piroctone olamine (C/P moisturizer that does not contain climbazole and pir- cream) (Sensibio DS+Ⓡ; Bioderma Laboratoire Dermatol- octone olamine, on the left side every morning and eve- ogique, Lyon, France) tested in this study is a cosmetic ning for 4 weeks. The use of other cosmetics, therapeutic product containing piroctone olamine and climbazole. external preparations, and drugs that could affect the clin- Piroctone olamine, the ethanolamine salt of the hydroxa- ical trial was prohibited during the study. At the baseline mic acid derivative piroctone, is a hydroxypyridone an- visit and at 4 weeks, (1) SebumeterⓇ and MexameterⓇ ti-mycotic agent. Climbazole is an imidazole antifungal (Courage & Khazaka Electronic GmbH, Cologne, Germany) agent. A non-steroidal cream containing piroctone olamine were used to measure the casual sebum level and most in- was reported to effectively treat SD by inhibiting the tense erythema on the forehead and cheek on both sides; growth of Malassezia species7, and a shampoo containing and (2) patients were asked to subjectively score their itch- piroctone olamine and climbazole effectively reduced iness, burning sensation, erythema, scaling, and tightness dandruff by suppressing the growth of Malassezia8. on each side of the face as none, 0; mild, 1; moderate, 2; However, no study thus far has reported on an over- or severe, 3. This research was conducted in winter from the-counter product containing piroctone olamine and November to December. climbazole for the treatment of facial SD. We aimed to Safety evaluation evaluate the efficacy and safety of C/P cream in the treat- ment of facial SD. Safety was assessed by inquiring about local irritation or other adverse events by using questionnaires. MATERIALS AND METHODS Antifungal assay Patients To determine the antifungal activity of the C/P cream and This 4-week single-center, open-label split-face study was emollient cream against specific Malassezia species approved by the institutional review board of Konkuk strains, their minimal inhibitory concentrations (MICs) University Medical Center (IRB no. KUH1120054). All of were measured in a laboratory. MIC is the lowest concen- the patients included in this study signed an informed con- tration of antifungals or antibiotics that will inhibit the visi- sent form. The participants were 24 patients diagnosed ble growth of a microorganism after overnight incubation. with facial symmetric mild-to-moderate SD by a dermato- Malassezia restricta, M. sympodialis, and M. slooffiae logist. The severity of SD9 was determined by using two were isolated and identified at Konkuk University Medical scales; one scored erythema, plaque, infiltration, and pus- Center, South Korea, and M. globosa (Centraalbureau voor tules as absent (0), mild (1), moderate (2), or severe (3), Schimmelcultures [CBS] 7966) was purchased from the and the other scored the extent of lesions as less than 10% CBS Fungal Biodiversity Center. These strains were grown (1), 10%∼30% (2), 30%∼50% (3), 50%∼70% (4), or on Leeming and Notman agar medium10 (0.5% glucose, more than 70% (5). The total score was calculated by mul- 1% polypeptone, 0.01% yeast extract, 0.8% bile salt, tiplying the severity by the lesion area of erythema, plaque, 0.1% glycerol, 0.05% glycerol monostearate, 0.05% infiltration, and pustules, respectively, and adding the tween 60, 1.2% agar, 0.5% whole fat cow milk, and 170 scores of all four items. The total scores were categorised μg/ml chloramphenicol). Susceptibility testing of the C/P into mild (≤5 points), moderate (6∼11), or severe (12∼ cream and emollient cream was performed according to a 60). Patients who used any oral drug that could affect the method described previously11. Antifungal assays were re- condition of the skin (steroids, antibiotics, antifungal peated twice, and identical results were obtained. agents, antihistamines, etc.) within 4 weeks of study entry Statistical analysis or any therapeutic external preparation within 2 weeks of study entry were excluded. Patients with a skin disease The Wilcoxon signed rank test was used to compare the other than SD and those who underwent a facial proce- values in the C/P cream-treated area with respective val- dure within 6 months of study entry were excluded as ues in the emollient-treated area. Significance levels were well. set at p<0.05. Analyses were performed using SPSS ver. 23.0 for Windows (SPSS Inc., Chicago, IL, USA). Treatment and assessment The patients were instructed to apply C/P cream (Sensibio 734 Ann Dermatol Efficacy and Safety of C/P Cream for Facial SD Ⓡ Ⓡ RESULTS ing Sebumeter and Mexameter , and compared at base- line and 4 weeks. At week 4, the C/P cream-treated area Study population showed a statistically significant reduction in the median The patients’ mean age was 35.37 years. We enrolled 24 casual sebum level on the forehead (marked with a black Korean patients (6 men and 18 women), none of whom bold line in Fig. 1) compared to the emollient cream-treat- withdrew from the study. ed area (p=0.011). On the cheek, the C/P cream-treated area also showed a lower median casual sebum level Efficacy of the C/P cream in comparison with that of compared to the emollient-treated area, but this was not the emollient cream statistically significant (Fig. 1). At week 4, the C/P cream-treat- ed area showed a statistically significant reduction (p=0.002) 1) Assessment of the changes in the objective SD symptoms in median erythema level compared to the emollient The casual sebum level and extent of erythema on the left- cream-treated area, on both the forehead and the cheek and right-side forehead and cheek were measured by us- (Fig.
Recommended publications
  • A Comparison of Clinical Efficacy Between a Basic Shampoo With
    Original Article A Comparison of Clinical Efficacy between a Basic Shampoo with Herbal Extracts Containing Climbazole and Its Similar Sample Containing Piroctone Olamine in the Treatment of Dandruff and Seborrheic Dermatitis Hosein Rastegar, PhD1 Abstract Hamidreza Ahmadi Ashtiani, PhD Background: Dandruff especially with itching and inflammation is a Student2 common complaint among patients in the clinic and its treatment is Mohammad Baghaei, Pharm D3 much challenging. Chemical anti fungal substances used in Saeid Bokaei, PhD4 antidandruff shampoos are common treatments. The aim of this study 5 was to compare the clinical efficacy of two of these anti dandruff Amirhoushang Ehsani, MD substances, climbazole and piroctone olamine in the treatment of Pedram Noormohammadpour, MD5 dandruff and seborrheic dermatitis in shampoos with herbal extracts. 5 Sahar Azizahari, MD Methods: One hundred and twenty men with scalp dandruff of the Ramin Khanmohammad6 same severity, between 20-30 years old and in the same occupational condition in terms of sun exposure or environmental 1. Laboratory Research Centre of Food and pollution were selected and divided randomly into two 60-subject Drug, Ministry of Health and Medical groups. After each shampoo was applied 3 times a week for 5 Educations, Islamic Republic of Iran weeks one in group 1 and the other in group 2, patients were 2. Department of Clinical Biochemistry, assessed for existence of itching and redness of scalp and reduction School of Medical Science, Tarbiat-e- in dandruff and results were compared between two groups. Modarres University, Tehran, Iran and Biochemistry & Nutrition Department of Results: Itching and redness were completely cured in both groups Zanjan Medical University and Institute of after treatment.
    [Show full text]
  • Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007
    Contact Office of Imported Food Safety, Inspection and Safety Division, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare (extension: 2474, 2497, 2498) Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007 August 2008 Department of Food Safety Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007 Introduction The total number of foods, additives, equipment, containers and packages, and toys (hereinafter collectively referred to as “foods”) imported to Japan in FY2007 was about 1.80 million, with an imported weight of about 32.3 million tons. According to the Food Balance Sheet for FY 2007 by the Ministry of Agriculture, Forestry and Fisheries, the food self-sufficiency ratio in Japan (food self-sufficiency ratio based on the total caloric value supplied) was estimated at 40%, indicating that, on a calorie basis, approximately 60% of foods consumed in Japan are imported. Regarding the monitoring and guidance conducted by the national government for the purpose of ensuring the safety of foods imported to Japan (hereinafter referred to as “imported foods”), the Imported Foods Monitoring and Guidance Plan for FY2007 (hereinafter referred to as the “Plan”) was developed based on public comments and risk communications, and was conduced in line with the Guidelines for the Implementation of Monitoring and Guidance on Food Sanitation (Notification No. 301 of the Ministry of Labour, Health and Welfare, 2003) under Article 23, paragraph 1 of the Food Sanitation Law (Law No.
    [Show full text]
  • Development and Validation of UV Spectroscopic Method for Estimation of Climbazole in Climbazole Shampoo
    RESEARCH ARTICLE Am. J. PharmTech Res. 2020; 10(01) ISSN: 2249-3387 Journal home page: http://www.ajptr.com/ Development and Validation of UV Spectroscopic Method for Estimation of Climbazole in Climbazole Shampoo Rajashree N. Patil*1, Pratiksha A. Patil1, Swapnil R. Patil2, Amol Sawale2 1.Department of Pharmaceutical Chemistry, Arunamai College of Pharmacy, Mamurabad, North Maharashtra University, Jalgaon (MH) INDIA 425002. 2.Department of Pharmaceutics and Quality Assurance, Vidya Bharati College of Pharmacy, Amravati University, Amravati (MH) INDIA 444602. ABSTRACT To develop and validate simple, rapid, linear, accurate, precise and economical UV Spectroscopic method for estimation of Climbazole in Climbazole shampoo. The drug is freely soluble in organic solvents such as Chloroform and Methanol. The drug was identified in terms of solubility studies and on the basis of melting point done on Melting Point Apparatus of Equiptronics. It showed absorption maxima were determined in Methanol: Water (50:50). The drug obeyed the Beer’s law and showed good correlation of concentration with absorption which reflect in linearity. The UV spectroscopic method was developed for estimation of Climbazole in shampoo dosage form and also validated as per ICH guidelines. The drug is freely soluble in organic solvents such as Methanol, Chloroform. So, the Analytical Grade Methanol: Water is used as a diluent in equal proportion for method. The melting point of Climbazole was found to be 93-94˚C (uncorrected). It showed absorption maxima 256 nm in Methanol: Water (50:50). On the basis of absorption spectrum the working concentration was set on 6µg/ml (PPM). The linearity was observed between 2-10 μg/ml (PPM).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,911,795 B2 Schmaus Et Al
    US00891. 1795B2 (12) United States Patent (10) Patent No.: US 8,911,795 B2 Schmaus et al. (45) Date of Patent: *Dec. 16, 2014 (54) COMPOSITIONS COMPRISING (52) U.S. Cl. DHYDROAVENANTHRAMIDED AND CPC ............. A61O5/006 (2013.01); A61 K 2800/75 CLIMBAZOLEAS COSMETIC AND (2013.01); A61 K31/196 (2013.01); A61 K PHARMACEUTICAL COMPOSITIONS FOR 8/445 (2013.01); A61O 19/00 (2013.01) ALLEVIATING ITCHING USPC ............ 424/640; 514/188: 514/345; 514/563 (58) Field of Classification Search (75) Inventors: Gerhard Schmaus, Höxter (DE); None Joachim Röding, Badenweiler (DE) See application file for complete search history. (73) Assignee: Symrise AG, Holzminden (DE) (56) References Cited U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 4,070,484 A 1/1978 Harita et al. 8,409,552 B2 * 4/2013 Schmaus et al. ................ 424,61 U.S.C. 154(b) by 1390 days. 2003/0161802 A1* 8, 2003 Flammer et al. ............. 424.70.1 This patent is Subject to a terminal dis 2003/0228272 Al 12/2003 Amjad et al. claimer. 2006/0089413 A1* 4/2006 Schmaus et al. .............. 514,563 (21) Appl. No.: 12/095,453 FOREIGN PATENT DOCUMENTS JP 2005187398 7/2005 (22) PCT Filed: Nov. 3, 2006 WO WO-2004O35O15 4/2004 WO WO 2004/047833 * 6, 2004 ........... A61K 31,196 (86). PCT No.: PCT/EP2006/068077 WO WO-2004O47833 6, 2004 WO WO-2006134013 12/2006 S371 (c)(1), WO WO-2006134120 12/2006 (2), (4) Date: Apr. 23, 2009 OTHER PUBLICATIONS (87) PCT Pub.
    [Show full text]
  • Climbazole Is a New Potent Inducer of Rat Hepatic Cytochrome P450
    The Journal of Toxicological Sciences, 141 Vol.26, No.3, 141―150, 2001 CLIMBAZOLE IS A NEW POTENT INDUCER OF RAT HEPATIC CYTOCHROME P450 Yasuna KOBAYASHI1, Michiya SUZUKI2, Naomi OHSHIRO1, Takashi SUNAGAWA2, Tadanori SASAKI1, Shogo TOKUYAMA1, Toshinori YAMAMOTO1 and Takemi YOSHIDA2 1Departments of Clinical Pharmacy and 2Biochemical Toxicology, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo142-8555, Japan (Received March 19, 2001; Accepted April 25, 2001) ABSTRACT ― We examined the effect of climbazole on the induction of rat hepatic microsomal cytochrome P450 (P450), and compared the induction potency with other N-substituted azole drugs such as clorimazole. We found that climbazole is found to be a potent inducer of rat hepatic microsomal P450 as clorimazole. Induced level of P450 by climbazole was almost similar in extent to clorimazole when compared with other imidazole drugs in a dose- and time-dependent manner. Parallel to the increase in P450, climbazole increased aminopyrine and erythromycin N-demethylase, ethoxycoumarin O-deethylase, and androstenedione 16β- and 15α/6βhydroxylase activities; however, clorimazole did not induce aminopyrine N-demethylase activity irrespective of its marked increase in P450 content. Immunoblot analyses revealed that climbazole induced CYP2B1, 3A2 and 4A1. The present findings indicate that climbazole is a new potent inducer of hepatic microsomal P450 and drug-metabolizing enzymes like clori- mazole, but it may have some differential mechanism(s) for these enzymes’ induction in rat liver. KEY WORDS: Climbazole, Cytochrome P450, Imidazole, Enzyme induction INTRODUCTION ducing P450 induction. Additionally, we have shown that 1-trityl- and 1-diphenylmethyl-imidazoles induces Cytochrome P450 (P450) constitutes a superfami- CYP2B, whereas 1-benzylimidazole increases both ly of hemeproteins that play a pivotal role in the metab- CYP2B and CYP1A species (Kobayashi et al., 1993).
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,834,409 Ramachandran Et Al
    USOO5834.409A United States Patent (19) 11 Patent Number: 5,834,409 Ramachandran et al. (45) Date of Patent: *Nov. 10, 1998 54 SCALP CARE PRODUCTS CONTAINING 4,867,971 9/1989 Ryan et al. ............................... 424/81 ANTI ITCHING/ANTI IRRITANT AGENTS 4.885,107 12/1989 Wetzel ... 252/106 4,895,727 1/1990 Allen ... ... 424/642 (75) Inventors: Pallassana Narayanier 4,921,170 5/1990 Grollier ................................... 239/304 4,925,659 5/1990 Grollier et al. ........................... 424/78 Ramachandran, Robbinsville; 4997,641 3/1991 Hartnett et al. ... 424/70 Clarence Ralph Robbins, Martinsville; 4,999,195 3/1991 Hayes.............. ... 424/114 Amrit Manilal Patel, Dayton, all of 5,002,761 3/1991 Mueller et al. ... 424/70 N.J. 5,051,250 9/1991 Patel et al. ... ... 424/70 5,091,171 2/1992 Yu et al. ......... 424/642 73) Assignee: Colgate-Palmolive Company, New 5,100,658 3/1992 Bolich, Jr. et al. ... 424/70 York, N.Y. 5,104,646 4/1992 Bolich, Jr. et al. ..... ... 424/70 5,106,609 4/1992 Bolich, Jr. et al. ... 424/70 Notice: This patent issued on a continued pros 5,106,613 4/1992 Hartnett et al. ........................... 424/71 ecution application filed under 37 CFR 5,151,209 9/1992 McCall et al... 252/174.15 1.53(d), and is subject to the twenty year 5,213,716 5/1993 Patel et al. .............................. 252/547 patent term provisions of 35 U.S.C. 5,346,642 9/1994 Patel et al. 252/174.21 5,348,736 9/1994 Patel .........................................
    [Show full text]
  • Topical Antifungals Used for Treatment of Seborrheic Dermatitis
    Journal of Bacteriology & Mycology: Open Access Review Article Open Access Topical antifungals used for treatment of seborrheic dermatitis Abstract Volume 4 Issue 1 - 2017 Seborrheic dermatitis is a common inflammatory condition mainly affecting scalp, Sundeep Chowdhry, Shikha Gupta, Paschal face and other seborrheic sites, characterized by a chronic relapsing course. The mainstay of treatment includes topical therapy comprising antifungals (ketoconazole, D’souza Department of Dermatology, ESI PGIMSR, India ciclopirox olamine) and anti-inflammatory agents along with providing symptomatic relief from itching. Oral antifungals and retinoids are indicated only in the severe, Correspondence: Sundeep Chowdhry, Senior Specialist and recalcitrant cases. The objective of this review is to discuss various topical antifungals Assistant Professor, Department of Dermatology, ESI PGIMSR, available for use in seborrheic dermatitis of scalp, face and flexural areas, discuss their Basaidarapur, New Delhi, India, Tel 919910084482, efficacy and safety profiles from relevant studies available in the literature along with Email [email protected] upcoming novel delivery methods to enhance the efficacy of these drugs. Received: October 28, 2016 | Published: January 06, 2017 Keywords: seborrheic dermatitis, antifungal agents, ketoconazole, ciclopirox Introduction Discussion Seborrheic dermatitis (SD) is a common, chronic inflammatory Treatment considerations disease that affects around 1-3% of the general population in many countries including the U.S., 3-5% of patients consisting of young Treatment for SD should aim for not just achieving remission of adults. The incidence of the disease has two peaks: one in newborn lesions but also to eliminate itching and burning sensation and prevent 6 infants up to three months of age, and the other in adults of around recurrence of the disease.
    [Show full text]
  • Topical Delivery of Climbazole to Mammalian Skin T ⁎ Miguel Paz-Alvareza, , Paul D.A
    International Journal of Pharmaceutics 549 (2018) 317–324 Contents lists available at ScienceDirect International Journal of Pharmaceutics journal homepage: www.elsevier.com/locate/ijpharm Topical delivery of climbazole to mammalian skin T ⁎ Miguel Paz-Alvareza, , Paul D.A. Pudneyb, Jonathan Hadgrafta, Majella E. Lanea a UCL School of Pharmacy, 29-39 Brunswick Square, WC1N 1AX London, UK b Strategic Science Group, Unilever R&D, Colworth Science Park, MK44 1LQ, Sharnbrook, Bedford, UK ARTICLE INFO ABSTRACT Keywords: Dandruff is a common condition, affecting up to half the global population of immunocompetent adults at some In vitro time during their lives and it has been highly correlated with the over-expression of the fungus Malassezia spp. Porcine skin Climbazole (CBZ) is used as an antifungal and preservative agent in many marketed formulations for the Human skin treatment of dandruff. While the efficacy of CBZ in vitro and in vivo has previously been reported, limited in- Finite dose formation has been published about the uptake and deposition of CBZ in the skin. Hence, our aim was to Infinite dose investigate the skin permeation of CBZ as well as the influence of various solvents on CBZ skin delivery. Four Climbazole solvents were selected for the permeability studies of CBZ, namely propylene glycol (PG), octyl salicylate (OSal), Transcutol® P (TC) and polyethylene glycol 200 (PEG). The criteria for selection were based on their wide use as excipients in commercial formulations, their potential to act as skin penetration enhancers and their favourable safety profiles. 1% (w/v) solutions of CBZ were applied under infinite and finite dose conditions using Franz type diffusion cells to human and porcine skin.
    [Show full text]
  • The Management of Seborrheic Dermatitis 2020: an Update
    Review Article The management of seborrheic dermatitis 2020: An update Sandra Widaty1, Kusmarinah Bramono1, Muhammad Yulianto Listiawan2, Ariyati Yosi3, Eliza Miranda1, Githa Rahmayunita1, Herwinda Brahmanti4, Henry W Lim5 1Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia 2Department of Dermatology and Venereology, Faculty of Medicine Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia 3Department of Dermatology and Venereology, Faculty of Medicine Universitas Sumatera Utara, H. Adam Malik General Hospital, Medan, Indonesia 4Department of Dermatology and Venereology, Faculty of Medicine Universitas Brawijaya, Dr. Saiful Anwar General Hospital, Malang, Indonesia 5Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA Email: [email protected] Abstract Background: Seborrheic dermatitis (SD) is a chronic relapsing dermatitis manifesting in the seborrheic area, affecting infants or adults. In Indonesia, the prevalence of SD is 0.99–5.8% of all dermatology cases from 2013 to 2015. SD has been known to be a prominent manifestation among HIV patients, but there is an increasing trend in the general population. Therefore, in 2017, the Indonesian Society for Dermatology and Venereology proposed a consensus for the management of SD in Indonesia based on the discussion from 12 dermatological centers. Concurrent with the development of new drugs, this study aims to evaluate and develop a guideline for the treatment of seborrheic dermatitis in Indonesia to update the previous guidelines in 2017. Methods: Systematic review was based on evidence-based methods, and scientific evidences were acquired through systematic search. Evidence analysis was in accordance with the level of evidence. The available evidences were evaluated, and conclusion was based on the grade of recommendation.
    [Show full text]
  • Open Access Article Under the CC by License (
    Molecular and Cellular Endocrinology 524 (2021) 111168 Contents lists available at ScienceDirect Molecular and Cellular Endocrinology journal homepage: www.elsevier.com/locate/mce Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess Katharina R. Beck, Alex Odermatt * Swiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland ARTICLE INFO ABSTRACT Keywords: The syndromes of mineralocorticoid excess describe a heterogeneous group of clinical manifestations leading to Hypertension endocrine hypertension, typically either through direct activation of mineralocorticoid receptors or indirectly by Mineralocorticoid excess impaired pre-receptor enzymatic regulation or through disturbed renal sodium homeostasis. The phenotypes of Azole antifungal these disorders can be caused by inherited gene variants and somatic mutations or may be acquired upon ex­ Adverse drug reaction posures to exogenous substances. Regarding the latter, the symptoms of an acquired mineralocorticoid excess CYP11B 11β-hydroxysteroid dehydrogenase have been reported during treatment with azole antifungal drugs. The current review describes the occurrence of mineralocorticoid excess particularly during the therapy with posaconazole and itraconazole, addresses the underlying mechanisms as well as inter- and intra-individual differences, and proposes a therapeutic drug monitoring strategy for these two azole antifungals. Moreover, other therapeutically used azole antifungals and ongoing efforts to avoid adverse mineralocorticoid effects of azole compounds are shortly discussed. may often be unrecognized. The following sections cover the targets and mechanisms involved in SME, followed by a discussion of recent findings 1. Introduction on azole antifungals causing acquired SME. The management and prevention of hypertension represents an 2. Targets of mineralocorticoid excess and underlying important global health challenge.
    [Show full text]
  • Anti-Fungal Compounds: Emerging Environmental Contaminants
    Anti-fungal compounds: emerging environmental contaminants Azole fungicides are active ingredients in a range of pharmaceutical and personal care products, and are also used in agriculture. This study reviewed 23 September 2016 the sources, presence and risks of these compounds in the environment, finding Issue 471 evidence of toxic effects on aquatic organisms. The researchers provide directions Subscribe to free for future research and warn caution should be exercised until more toxicity data weekly News Alert becomes available. Source: Chen, Z. & Ying, G. Azole fungicides are used to treat fungal infections in agriculture and human (2015). Occurrence, fate and medicine. Usually administered in the form of tablets and ointments, azole fungicides can ecological risk of five typical also be found in common household products, from shampoo and soap to toothpaste and azole fungicides as therapeutic shower gel. Climbazole, which is used in anti-dandruff shampoos and anti-ageing creams, is and personal care products in reportedly used in Europe at a rate of 100–1 000 tonnes per year1. the environment: A review. Environment International, Over the past 10 years, these compounds have emerged as a new class of environmental 84: 142–153. DOI: 10.1016/ pollutants. After use, they are flushed into wastewater treatment plants (WWTPs) and j.envint.2015.07.022. released into rivers where they may have adverse effects on non-target organisms. They are mainly emitted via hospital and municipal wastewater treatment plants. Contact: [email protected], This study investigated the occurrence, life cycle in the environment and toxic effects of the [email protected] five most commonly used azole fungicides: climbazole, clotrimazole, ketoconazole, Read more about: miconazole and fluconazole (most of which are authorised in the EU for use in either human or veterinary medicines and none of which is approved as an active substance to be used in Chemicals, Risk plant-protection products).
    [Show full text]
  • Seborrheic Dermatitis and Its Relationship with Malassezia Spp
    REVIEW Seborrheic dermatitis and its relationship with Malassezia spp Manuel Alejandro Salamanca-Córdoba†,1,2, Carolina Alexandra Zambrano-Pérez2,3, Carlos Mejía-Arbeláez2,4, Adriana Motta5, Pedro Jiménez6, Silvia Restrepo-Restrepo7, Adriana Marcela Celis-Ramírez1,8* Abstract Seborrheic dermatitis (SD) is a chronic inflammatory disease that that is difficult to manage and with a high impact on the individual’s quality of life. Besides, it is a multifactorial entity that typically occurs as an inflammatory response toMalassezia species, along with specific triggers that contribute to its pathophysiology. Sin- ce the primary underlying pathogenic mechanisms include Malassezia proliferation and skin inflammation, the most common treatment includes topical antifungal keratolytics and anti-inflammatory agents. However, the consequences of eliminating the yeast population from the skin, the resistance profiles ofMalassezia spp. and the effectivity among different groups of medications are unknown. Thus, in this review, we summarize the current knowledge on the disease´s pathophysio- logy and the role of Malassezia sp. on it, as well as, the different antifungal treatment alternatives, including topical and oral treatment in the management of SD. Key words: seborrheic dermatitis, Malassezia, pathogenic role, treatment. Dermatitis seborreica y su relación con Malassezia spp Resumen La dermatitis seborreica (DS) es una enfermedad inflamatoria crónica, con un elevado impacto en la calidad de vida del individuo. Además, DS es una entidad multifactorial que ocurre como respuesta inflamatoria a las levaduras del género Malassezia spp., junto con factores desencadenantes que contribuyen a la fisio- patología de la enfermedad. Dado que el mecanismo patogénico principal involucra la proliferación e inflamación generada por Malassezia spp., el tratamiento más usado son los agentes tópicos antifúngicos y antiinflamatorios.
    [Show full text]